SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with untreatable autoimmune diseases
Disease control Recruiting nowThis early-stage study is testing a new cell therapy called CAR-NK for children with severe rheumatic diseases that haven't responded to standard treatments. Doctors will give a single infusion of these specially modified immune cells to see if it's safe and can help put the dise…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Apr 01, 2026 19:56 UTC
-
Radical cell therapy tested for Hard-to-Treat lupus
Disease control Recruiting nowThis early-stage trial is testing a type of cell therapy called CAR T-cells in people with severe, treatment-resistant lupus. The study aims to find a safe dose and see if the therapy can help control the disease. It will enroll 18 participants aged 3 to 65 who have not responded…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Lupus patients continue treatment in Follow-Up study
Disease control Recruiting nowThis study allows patients with lupus who completed two previous trials to continue taking the medication deucravacitinib. The goal is to maintain disease control for those who benefited from the drug. Only 35 participants who finished the earlier studies are eligible to join.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New lupus drug trial seeks to tame overactive immune system
Disease control Recruiting nowThis study is testing a new drug called YK012 for adults with moderate to severe lupus. The main goals are to check the drug's safety, how the body processes it, and to see if it can help reduce lupus disease activity. Participants will receive the drug while continuing their sta…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New cell therapy tested for patients Who've tried everything else
Disease control Recruiting nowThis is an early safety study testing a single infusion of a new cell therapy called YTS109. It aims to see if the treatment is safe and shows any signs of helping adults with severe autoimmune diseases that have not responded to standard treatments. The study will enroll about 1…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug tested for kids with Tough-to-Treat lupus
Disease control Recruiting nowThis early-stage study is testing whether a drug called blinatumomab is safe and can help children and young adults with severe, treatment-resistant lupus. Participants will receive two short courses of injections and be closely monitored for a full year. The main goal is to see …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Mao Jianhua • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New lupus drug enters first human safety tests
Disease control Recruiting nowThis is an early-stage study to check the safety and how the body processes a new drug called PIT565 for people with active lupus (SLE). It will involve about 54 participants who haven't responded well to standard treatments. The main goal is to find a safe dose and see how the d…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Early trial tests 'Universal' cell therapy for devastating lupus
Disease control Recruiting nowThis is an early-stage study testing a new type of cell therapy for people with moderate to severe lupus that hasn't responded to standard treatments. The therapy, called CT1192, involves giving patients specially modified immune cells (CAR-T cells) designed to target and remove …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Experimental 'Triple-Target' drug tested for stubborn autoimmune illnesses
Disease control Recruiting nowThis early study is testing the safety of a new drug called CC312 in adults with severe autoimmune diseases that have not improved with standard treatments. The drug works by engaging the body's own immune T cells to attack harmful B cells, using a mechanism similar to some advan…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Experimental cell therapy targets tough lupus cases
Disease control Recruiting nowThis early-stage study is testing a new type of cell therapy called universal CD19/CD20 CAR-T for people with moderate to severe lupus that hasn't improved with standard treatments. The main goals are to find a safe dose and see how the body reacts to the treatment. Researchers w…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New lupus drug enters human testing
Disease control Recruiting nowThis early-stage study is testing a new drug called DB-2304 for lupus. It will first check the drug's safety and side effects in healthy volunteers, then in people with lupus. The main goal is to see how well the body tolerates the drug and how it behaves in the bloodstream.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Breakthrough trial aims to ditch damaging steroids for lupus patients
Disease control Recruiting nowThis major Phase 3 trial is testing if a new drug combination can effectively treat lupus nephritis (a serious kidney complication of lupus) without needing high doses of oral steroids. The study will compare the standard steroid-based treatment against a new regimen using a drug…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
One-Shot gene therapy trial aims to reset immune system in devastating diseases
Disease control Recruiting nowThis is an early-stage study testing a new, one-time treatment called TI-0032-III injection for people with severe autoimmune diseases that have not improved with standard medications. The treatment uses a single injection of genetic material to reprogram the patient's own immune…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Therorna • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New cell therapy tested for patients with untreatable autoimmune diseases
Disease control Recruiting nowThis is an early-stage study to check the safety of a new cell therapy called YTS109 for adults with severe autoimmune diseases that have not responded to standard treatments. About 18 participants with conditions like lupus, scleroderma, or vasculitis will receive a single infus…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New lupus drug enters human testing phase
Disease control Recruiting nowThis early-stage study is testing a new drug called cizutamig in people with systemic lupus erythematosus (lupus). The main goal is to check if the drug is safe and how the body handles it, in 47 adults with active lupus. Researchers will monitor side effects and how the drug mov…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug trial seeks to calm overactive immune system
Disease control Recruiting nowThis is a first-in-human study to check if a new injectable drug called VIS171 is safe for people with certain autoimmune diseases like lupus, alopecia areata, or a kidney disease called FSGS. About 30 participants will receive the drug along with their standard care for up to a …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New 'Living Drug' trial offers hope for Tough-to-Treat lupus
Disease control Recruiting nowThis is an early-stage trial testing a new type of personalized cell therapy called MC-1-50 for adults with severe, treatment-resistant lupus. The main goal is to check the safety and side effects of three different doses of these specially engineered immune cells. Researchers wi…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Groundbreaking cell therapy trial offers hope for young lupus patients
Disease control Recruiting nowThis study is testing a personalized cell therapy called CART19 for adolescents and young adults with severe lupus that hasn't responded to standard treatments. Doctors will collect a patient's own immune cells, modify them to target lupus-causing B cells, and reinfuse them. The …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
Global study tracks new lupus drug in everyday use
Disease control Recruiting nowThis study is observing how well the medication anifrolumab works for people with lupus when used in regular doctor's offices, not just in clinical trials. It will follow 200 patients across several countries for one year to see how their symptoms, skin problems, and quality of l…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
First human tests begin for promising new autoimmune disease drug
Disease control Recruiting nowThis early-stage study is testing a new drug called SAR448501 in adults with moderate-to-severe lupus or rheumatoid arthritis who haven't gotten enough relief from their current treatments. The main goal is to find safe dose levels and see how the drug behaves in the body. About …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
First-in-Human trial tests 'Living Drug' for tough autoimmune cases
Disease control Recruiting nowThis is an early safety study to test a new type of treatment called LUCAR-G79D, a CAR-T cell therapy, in adults with severe lupus or inflammatory muscle disease that has not responded to other treatments. The main goal is to see if the treatment is safe, how the body handles it,…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Early trial tests stem cell shot for lupus control
Disease control Recruiting nowThis early-stage study is testing whether adding a single injection of stem cells from umbilical cords to standard lupus treatment is safe and tolerable. It will involve 10 adults with active lupus to see if the therapy can reduce disease activity and improve kidney function. The…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: LiveKidney.Bio • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New cell therapy enters human testing for devastating autoimmune conditions
Disease control Recruiting nowThis is a first-in-human study to check the safety and early effects of an experimental cell therapy called FT819. It is for people aged 12-70 with moderate to severe forms of four serious autoimmune diseases (lupus, vasculitis, myositis, or scleroderma) that haven't responded we…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New cell therapy tested for Hard-to-Treat autoimmune conditions
Disease control Recruiting nowThis is an early-stage study to check the safety of a new cell therapy called YTS109 in adults with severe autoimmune diseases that have not improved with standard treatments. About 18 participants with conditions like lupus, Sjogren's syndrome, or vasculitis will receive a singl…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Breakthrough biologics battle standard lupus treatment in kidney trial
Disease control Recruiting nowThis study compares two newer biologic drugs (belimumab and telitacicept) against the current standard treatment for lupus nephritis, a serious kidney complication of lupus. Fifty patients with active kidney inflammation will receive either a biologic drug alone, standard therapy…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Nanjing University School of Medicine • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
Radical cell therapy tested for Tough-to-Treat lupus
Disease control Recruiting nowThis early-stage study is testing a new type of treatment called universal anti-CD70 CAR-T (CHT101) for people with severe lupus that hasn't responded to standard medications. It aims to see if this advanced cell therapy is safe and can effectively control the disease. The study …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Universal CAR-T cells tested as potential new weapon against severe lupus
Disease control Recruiting nowThis early-phase study is testing a new cell therapy called QT-019B for people with severe lupus that hasn't responded to standard treatments. The therapy uses 'universal' CAR-T cells from healthy donors, designed to target and remove certain immune cells thought to drive lupus. …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Hangzhou Qihan Biotech Co., Ltd. • Aim: Disease control
Last updated Mar 16, 2026 15:23 UTC
-
Radical cell therapy tested for devastating autoimmune diseases
Disease control Recruiting nowThis early-stage study is testing a new treatment called CT1190B CAR-T cell therapy for adults with severe lupus or scleroderma that hasn't responded to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to potentially fight the disease, …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
Could a vitamin boost calm the raging immune system in lupus?
Disease control Recruiting nowThis study is testing if a supplement called nicotinamide riboside (NR), a form of vitamin B3, can help control lupus in women. Researchers want to see if boosting a cell's energy molecule (NAD+) can reduce harmful inflammation and improve blood vessel health. The trial will comp…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Mar 09, 2026 14:24 UTC
-
Radical cell therapy tested for Tough-to-Treat autoimmune illnesses
Disease control Recruiting nowThis early-stage study is testing the safety and initial effectiveness of a new cell therapy called BZE2204 for adults with severe autoimmune diseases that have not improved with standard treatments. The therapy involves modifying a patient's own immune cells to target and potent…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Cell Therapy Group Co.,Ltd • Aim: Disease control
Last updated Mar 06, 2026 15:39 UTC
-
New antibody treatment trial offers hope for lupus patients
Disease control Recruiting nowThis study is testing an experimental antibody called SSGJ-626 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. Researchers will compare SSGJ-626 plus standard care against placebo plus standard care in 198 adults with active lupus symptoms. The g…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Mar 02, 2026 15:28 UTC
-
Heart scans could spot severe lupus in kids sooner
Knowledge-focused Recruiting nowThis study aims to find early signs of severe lupus in children by looking at their heart function. Researchers will use non-invasive heart scans (echocardiograms) on 60 children with lupus to see if changes in heart muscle can predict which kids have a harder-to-treat form of th…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
Researchers track Real-World results for Tough-to-Treat lupus cases
Knowledge-focused Recruiting nowThis study aims to understand how well current standard treatments work for people with active systemic lupus erythematosus (SLE), including lupus affecting the kidneys, who haven't responded well to steroids and at least two other immune-suppressing drugs. Researchers will obser…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:33 UTC
-
10,000 lupus patients sought for major online survey to shape future care
Knowledge-focused Recruiting nowThis is a large online registry, not a treatment study. Its purpose is to collect information directly from up to 10,000 people living with lupus to better understand their diagnosis journey, treatments, and how the disease affects their daily life and work. Participants complete…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Lupus Foundation of America • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:27 UTC